-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Neutral on Zentalis Pharma, Maintains $4 Price Target

Benzinga·05/15/2025 14:52:08
Listen to the news
Wedbush analyst Robert Driscoll reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Neutral and maintains $4 price target.